Spero Therapeutics Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Sath Shukla

Chief Executive Officer (CEO)

US$2.0m

Compensación total

Porcentaje del salario del CEO	25.9%
Permanencia del CEO	less than a year
Participación del CEO	n/a
Permanencia media de la dirección	1.5yrs
Promedio de permanencia en la Junta Directiva	10yrs

Actualizaciones recientes de la dirección

Recent updates

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Apr 23

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Mar 12

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Jan 02

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

May 18

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Apr 17

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Apr 13

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Apr 05

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Oct 03

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) CEO Compensation Looks Acceptable To Us And Here's Why

Aug 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Sath Shukla en comparación con los beneficios de Spero Therapeutics?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2024	n/a	n/a	US$23m
Dec 31 2023	US$2m	US$524k	US$23m
Sep 30 2023	n/a	n/a	-US$2m
Jun 30 2023	n/a	n/a	-US$10m
Mar 31 2023	n/a	n/a	-US$27m
Dec 31 2022	US$2m	US$478k	-US$46m
Sep 30 2022	n/a	n/a	-US$102m
Jun 30 2022	n/a	n/a	-US$113m
Mar 31 2022	n/a	n/a	-US$103m
Dec 31 2021	US$2m	US$441k	-US$90m

Compensación vs. Mercado: La compensación total de Sath($USD2.02M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Sath ha sido consistente con los resultados de la empresa en el último año.

CEO

Sath Shukla (50 yo)

less than a year

Permanencia

US$2,024,647

Compensación

Mr. Satyavrat Shukla, also known as Sath, C.F.A., has been President, Chief Executive Officer and Director at Spero Therapeutics, Inc. since August 1, 2023. He had been the Chief Financial Officer of Spero...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ankit Mahadevia	Co-Founder & Chairman of the Board	10.7yrs	US$2.39m	0.41% $ 349.6k
Satyavrat Shukla	President	less than a year	US$2.02m	sin datos
Timothy Keutzer	Chief Operating Officer	1.3yrs	US$1.44m	0.12% $ 101.5k
Esther Rajavelu	CFO, Chief Business Officer & Treasurer	less than a year	sin datos	sin datos
James Brady	Chief Human Resource Officer	2.5yrs	sin datos	sin datos
Kamal Hamed	Chief Medical Officer	1.7yrs	sin datos	0.23% $ 193.1k

1.5yrs

Permanencia media

50yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SPRO no se considera experimentado ( 1.4 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ankit Mahadevia	Co-Founder & Chairman of the Board	10.7yrs	US$2.39m	0.41% $ 349.6k
Satyavrat Shukla	President	less than a year	US$2.02m	sin datos
Frank Thomas	Independent Director	6.8yrs	US$88.83k	0.028% $ 23.8k
Milind Deshpande	Independent Director	10.3yrs	US$105.70k	0.058% $ 50.0k
Eric Gordon	Scientific Advisors	10yrs	sin datos	sin datos
George Drusano	Clinical Advisor	10yrs	sin datos	sin datos
Steven Gilman	Scientific Advisor	no data	sin datos	sin datos
Patrick V. J. Vink	Lead Independent Director	8.7yrs	US$93.19k	0.028% $ 23.8k
Gordon Archer	Clinical Advisor	10yrs	sin datos	sin datos
David Livermore	Scientific Advisor	no data	sin datos	sin datos
Paul Ambrose	Clinical Advisor	10yrs	sin datos	sin datos
Cynthia Smith	Independent Director	5.2yrs	US$73.20k	0.028% $ 23.8k

10.0yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: Los miembros de la junta directiva de SPRO son experimentados ( 10 años antigüedad media).

Spero Therapeutics Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

President notifies of intention to sell stock

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Chief Medical Officer recently sold US$50k worth of stock

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Recent updates

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

Investor sentiment improves as stock rises 15%

Spero Therapeutics Delivers On Game Plan To Create Shareholder Value

Spero Therapeutics, Inc., Annual General Meeting, May 29, 2024

Consensus EPS estimates fall by 24%

Spero Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $75 million.

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. (NASDAQ:SPRO) Held Back By Insufficient Growth Even After Shares Climb 27%

Spero Therapeutics, Inc. to Report Q4, 2023 Results on Mar 13, 2024

New minor risk - Profitability

President notifies of intention to sell stock

Spero Therapeutics, Inc.'s (NASDAQ:SPRO) Share Price Boosted 26% But Its Business Prospects Need A Lift Too

Spero Therapeutics, Inc. Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections

Forecast to breakeven in 2026

New minor risk - Shareholder dilution

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus revenue estimates increase by 21%, EPS downgraded

Price target increased by 18% to US$7.50

Spero Therapeutics, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Spero Therapeutics Appoints Esther Rajavelu as Chief Business Officer

Consensus estimates of losses per share improve by 10%

Chief Medical Officer recently sold US$50k worth of stock

Spero Therapeutics, Inc., Annual General Meeting, Oct 05, 2023

Consensus estimates of losses per share improve by 38%

New major risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q2, 2023 Results on Aug 10, 2023

Consensus revenue estimates increase by 35%

Spero Therapeutics, Inc. Announces Chief Financial Officer Changes

Need To Know: Analysts Just Made A Substantial Cut To Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Estimates

Consensus revenue estimates fall by 36%

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. to Report Q1, 2023 Results on May 11, 2023

Spero Therapeutics, Inc. (NASDAQ:SPRO) Shares Fly 26% But Investors Aren't Buying For Growth

Industry Analysts Just Upgraded Their Spero Therapeutics, Inc. (NASDAQ:SPRO) Revenue Forecasts By 40%

Consensus revenue estimates increase by 40%

Consensus revenue estimates increase by 53%

We Think Spero Therapeutics (NASDAQ:SPRO) Can Easily Afford To Drive Business Growth

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics, Inc. Appoints Timothy Keutzer as Chief Operating Officer, Effective as of February 1, 2023

Consensus revenue estimates increase by 183%

Insufficient new directors

Spero Therapeutics, Inc. announced that it has received $8.999973 million in funding from GSK plc

Spero Therapeutics to Present Data at IDWeek 2022

Spero Therapeutics: The GlaxoSmithKline-Deal Changes Everything And Protects Shareholder Value

Spero Therapeutics, Inc. announced that it expects to receive $8.999973 million in funding from GSK plc

Spero Therapeutics Announces Appointment of Kamal Hamed as Chief Medical Officer

Spero Therapeutics appoints Kamal Hamed MD CMO

Spero Therapeutics Provides Tebipenem HBr Program Update Following Type A Meeting with the U.S. Food and Drug Administration

Spero jumps 64% as FDA clarifies future regulatory path for UTI candidate

Consensus revenue estimates increase by 69%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Spero Therapeutics GAAP EPS of -$0.87, revenue of $1.99M

Spero Therapeutics, Inc., Annual General Meeting, Sep 15, 2022

We're A Little Worried About Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

The Gross Law Firm Notifies Shareholders of Spero Therapeutics, Inc. of A Class Action Lawsuit

Spero Therapeutics, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration for Its New Drug Application

Pomerantz Law Firm Announces the Filing of Class Action Lawsuit Against Spero Therapeutics, Inc

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Spero Therapeutics, Inc. to Report Q1, 2022 Results on May 16, 2022

No longer forecast to breakeven

Consensus estimates of losses per share improve by 16%

Spero Therapeutics Announces New Strategic Direction Focusing on Advancing Promising Clinical-Stage Pipeline

Insufficient new directors

Consensus revenue estimates fall by 15%

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Price target decreased to US$35.80